Valneva (VALN) schedules Q1 2026 results webcast for May 13

Rhea-AI Filing Summary

Valneva SE, a specialty vaccine company listed on Nasdaq and Euronext Paris, announced it will report its first quarter 2026 consolidated financial results on May 13, 2026. The company will host a live webcast at 3 p.m. CET / 9 a.m. ET to discuss the results and provide a business update.

The webcast will be accessible via Valneva’s website and an archived version will be available after the event. The filing also reiterates Valneva’s focus on developing and commercializing prophylactic vaccines, including its Lyme disease and Shigella vaccine candidates, and includes standard forward-looking statements language about development, regulatory, and partnership risks.

Key Figures

Results date: May 13, 2026 Webcast time CET: 3 p.m. CET Webcast time ET: 9 a.m. ET

3 metrics

Results date May 13, 2026 Scheduled release of Q1 2026 consolidated financial results

Webcast time CET 3 p.m. CET Start time of Q1 2026 results webcast

Webcast time ET 9 a.m. ET Start time of Q1 2026 results webcast for U.S. audience

Key Terms

specialty vaccine company, prophylactic vaccines, forward-looking statements, technology transfer, +2 more

6 terms

specialty vaccine company financial

"Valneva SE ..., a specialty vaccine company, today announced"

prophylactic vaccines medical

"develops, manufactures, and commercializes prophylactic vaccines for infectious diseases"

forward-looking statements regulatory

"This press release contains certain forward-looking statements relating to the business of Valneva"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

technology transfer technical

"progress, timing, results and completion of technology transfer and regulatory approvals"

Technology transfer is the process of moving an invention, know‑how, or technical capability from one organization to another so it can be developed, manufactured or sold. For investors it matters because successful transfers turn research or prototypes into marketable products or revenue streams—similar to handing a recipe and kitchen to someone who can scale it up—and they affect a company’s growth prospects, costs, timelines and competitive position.

regulatory approvals regulatory

"completion of technology transfer and regulatory approvals in additional markets"

Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

clinical development medical

"the only Lyme disease vaccine candidate in advanced clinical development"

Clinical development is the process of testing a medical treatment in people to prove it is safe and works, moving from small early safety checks to larger trials that measure benefit and side effects. For investors it matters because each successful step reduces uncertainty and brings a product closer to regulatory approval and sales—like moving a prototype through road tests before mass production—while failures or delays can dramatically cut expected value.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 5, 2026

Commission File Number: 001-40377

Valneva SE

(Translation of registrant's name into English)

Îlot Saint-Joseph, Bureaux Convergence

12ter Quai Perrache

69002 Lyon, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On May 5, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K is hereby incorporated by reference into the registrant's registration Statement on Form F-3 (File No. 333-268071).

Exhibit
Exhibit 99.1			Press release dated May 5, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE (Registrant)

Date: May 5, 2026

/s/ Thomas Lingelbach

Thomas Lingelbach

Chief Executive Officer and President

Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026

Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update.

The live webcast will be accessible on the Company’s website and made available as an archive after the event concludes. Please refer to this link: https://edge.media-server.com/mmc/p/xbkzgkz7

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available on the Company’s website.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 Laetitia.BachelotFontaine@valneva.com Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of technology transfer and regulatory approvals in additional markets. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of

     VALNEVA SE

vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

2

FAQ

When will Valneva (VALN) report its Q1 2026 financial results?

Valneva will report its first quarter 2026 consolidated financial results on May 13, 2026. The company plans to accompany the release with a live webcast to discuss results and provide a broader business update for stakeholders.

What time is Valneva’s Q1 2026 results webcast and how can it be accessed?

The Q1 2026 webcast will begin at 3 p.m. CET / 9 a.m. ET. It will be streamed through Valneva’s website, and an archived version will be made available online after the live event concludes for later viewing.

What kind of company is Valneva (VALN)?

Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines. It targets infectious diseases with unmet medical needs and currently markets three proprietary travel vaccines while advancing a pipeline of additional vaccine candidates.

Which key vaccine candidates does Valneva highlight in this update?

Valneva highlights its Lyme disease vaccine candidate in advanced clinical development partnered with Pfizer, a clinically advanced Shigella vaccine candidate, and other vaccine programs targeting global public health threats, alongside its existing portfolio of three proprietary travel vaccines.

What forward-looking risks does Valneva mention in this communication?

Valneva notes that forward-looking statements involve risks such as development and manufacturing uncertainties, clinical trial outcomes, regulatory actions or delays, competitive pressures, currency fluctuations, credit conditions, and challenges in obtaining or maintaining patent and other intellectual property protection.

Will Valneva update its forward-looking statements after this announcement?

Valneva states it is providing this information as of the press release date and disclaims any intention or obligation to publicly update or revise forward-looking statements, whether due to new information, future events, or other developments affecting the business.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 9.8 KB